Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02083640 · ClinicalTrials.gov registry record · Phase 1
Relative Bioavailability For Palbociclib Formulations
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT02083640 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 30 participants.
The verdict
NCT02083640, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
This study is to assess the relative bioavailability of palbociclib hard gelatin capsule formulation (API 41 micrometer and dissolution Level 1) and palbociclib hard gelatin capsule formulation (API 16 micrometer and dissolution Level 2) compared to the palbociclib hard gelatin capsule formulation (API 16 micrometer and dissolution Level 1) after single 125 mg oral doses under fed conditions in healthy volunteers.
Interventions
- DRUG Palbociclib Formulation Reference
- DRUG Palbociclib Formulation Test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2014-03 |
| Est. Completion | 2014-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02083640
The ClinicalTrials.gov registry entry for NCT02083640 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Palbociclib Formulation Reference is the first listed.
NCT02083640 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02083640 about?
NCT02083640 is a clinical study titled "Relative Bioavailability For Palbociclib Formulations". This study is to assess the relative bioavailability of palbociclib hard gelatin capsule formulation (API 41 micrometer and dissolution Level 1) and palbociclib hard gelatin capsule formulation (API 16 micrometer and dissolution Level 2) compared to the palbociclib hard gelatin capsule formulation (...
What is the current status of trial NCT02083640?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2014-03. Estimated completion is 2014-05.
What interventions are being tested in trial NCT02083640?
The interventions under investigation include: Palbociclib Formulation Reference (DRUG), Palbociclib Formulation Test (DRUG).
Who is sponsoring clinical trial NCT02083640?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.